Rosetta Genomics To Market MicroRNA-based Diagnostics
Rosetta Genomics has entered into a co-marketing agreement for its miRview® mets2 assay for the identification of the tumor of origin in Cancers of Unknown or Uncertain Primary (“CUP”) with Precision Therapeutics Inc. Under the terms of the agreement, Rosetta Genomics granted Precision Therapeutics the co-exclusive right, along with Rosetta Genomics, to co-market the miRview® mets2 assay in the U.S. through July 30, 2014, with certain pre-specified performance milestones. According to the American Cancer Society, an estimated 2 to 5 percent of all cancer patients have metastatic (secondary) tumors for which routine testing cannot locate the primary site. This is called cancer of unknown primary origin (CUP). Patients may be diagnosed with cancer of unknown primary origin if the primary tumor is too small to be identified with routine imaging tests, it regresses (disappears) before a secondary tumor arises, or the secondary tumor has several possible primary sites. Cancer of unknown primary origin can appear anywhere in the body, but is most commonly found in the lymph nodes, liver, lungs, bones, or skin. miRview® are a series of microRNA-based diagnostic products offered by Rosetta Genomics. miRview® mets² identifies the primary tumor type in primary and metastatic cancer including Cancer of Unknown Primary (CUP). miRview® meso diagnoses mesothelioma, a cancer connected to asbestos exposure. In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the miRview® mets² test, 60,000 from miRview® meso, 54,000 from miRview® kidney and 226,000 patients from miRview® lung.